Study Summary
It is a single-center, open-labeled, single-arm, non-randomized, investigator-initiated trial aiming to evaluate the efficacy and safety of anti-CD19 CAR-T manufactured by OlyCAR platform (OlyCAR-019) for CD19+ refractory/relapsed B-Cell malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Anti-CD19 Autologous CAR-T Cell InfusionBIOLOGICAL
Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Kunming | Yunnan | China |